Does pay-for-performance program increase providers adherence to guidelines for managing Hepatitis B and Hepatitis C virus infection in Taiwan?

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Chen, Huei Ju ^a,b   Huang, Nicole ^a   Chen, Long Sheng ^b   Chou, Yiing Jenq ^a   Li, Chung Pin ^a,c   Wu, Chen Yi ^a,c   Chang, Yu Chia ^d,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Ministry of Health and Welfare   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; EXPERIMENTAL DESIGN; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT CARE; PAY FOR PERFORMANCE PROGRAM; PERSONNEL MANAGEMENT; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PROTOCOL COMPLIANCE; TAIWAN; YOUNG ADULT; ECONOMICS; HEALTH CARE PERSONNEL; METABOLISM; REIMBURSEMENT; STATISTICS AND NUMERICAL DATA;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; GUIDELINE ADHERENCE; HEALTH PERSONNEL; HEPATITIS B; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; REIMBURSEMENT, INCENTIVE; TAIWAN; YOUNG ADULT;

EID: 84983474393     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161002     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917. doi: 10.1002/ijc.25516 PMID: 21351269.
2. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii41-48. doi: 10.1093/annonc/mds225 PMID: 22997453.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245-1255. doi: 10.1016/s0140-6736(11)61347-0 PMID: 22353262.
4. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011; 29:3643-3650. doi: 10.1200/jco.2011.36.2335 PMID: 21859997.
5. Marrero CR, Marrero JA. Viral hepatitis and hepatocellular carcinoma. Arch Med Res. 2007; 38:612-620. doi: 10.1016/j.arcmed.2006.09.004 PMID: 17613352.
6. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009; 373:582-592. doi: 10.1016/s0140-6736 (09)60207-5 PMID: 19217993.
7. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3:47-52. PMID: 16614742.
8. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118-1127. doi: 10.1056/NEJMra1001683 PMID: 21992124
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50:661-662.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49:1335-1374. doi: 10.1002/hep.22759 PMID: 19330875.
11. Sargent S. Liver diseases: An essential guide for nurses and health care professionals. Oxford: Wiley-Blackwell. 2009:135-57.
12. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142:1264-1273. e1. doi: 10.1053/j.gastro.2011.12.061 PMID: 22537432.
13. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63(1):261-83. doi: 10.1002/hep.28156 PMID: 26566064.
14. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3):932-54. doi: 10. 1002/hep.27950 PMID: 26111063.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020-1022. doi: 10.1002/hep.24199 PMID: 21374666.
16. Amarapurkar D, Han KH, Chan HL, Ueno Y. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol. 2009; 24:955-961. doi: 10.1111/j.1440-1746.2009.05805.x PMID: 19383082.
17. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130:417-422. doi: 10.1007/s00432-004-0552-0 PMID: 15042359.
18. Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, Chen SL, et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology. 2014; 59:1840-1849. doi: 10. 1002/hep.26703 PMID: 24002724.
19. Wai CT, Mak B, Chua W, Lim SG. The majority of hepatitis B carriers are not on regular surveillance in Singapore. Singapore Med J. 2004; 45:423-426. PMID: 15334285.
20. Fang Q, Hao YH, Li L, Zhang ZH, Wang JZ, Chen MF, et al. Chronic HBV carrier's acceptance of regular surveilling program in China. J Huazhong Univ Sci Technolog Med Sci. 2013; 33:288-292. doi: 10. 1007/s11596-013-1113-z PMID: 23592146.
21. Khalili M, Guy J, Yu A, Li A, Diamond-Smith N, Stewart S, et al. Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers. Dig Dis Sci. 2011; 56:1516-1523. doi: 10.1007/s10620-010-1439-3 PMID: 21046247.
22. Tan NC, Cheah SL. What barriers do primary care physicians face in the management of patients with chronic hepatitis B infection in primary care? Singapore Med J. 2005; 46:333-339. PMID: 15968445.
23. Kim DY, Han KH. Epidemiology and Surveillance of Hepatocellular Carcinoma. Liver Cancer. 2012; 1:2-14. doi: 10.1159/000339016 PMID: 24159567.
24. Eijkenaar F, Emmert M, Scheppach M, Schoffski O. Effects of pay for performance in health care: a systematic review of systematic reviews. Health Policy. 2013; 110:115-130. doi: 10.1016/j.healthpol. 2013.01.008 PMID: 23380190.
25. Greene SE, Nash DB. Pay for performance: an overview of the literature. Am J Med Qual. 2009; 24:140-163. doi: 10.1177/1062860608326517 PMID: 18984907.
26. Van Herck P, De Smedt D, Annemans L, Remmen R, Rosenthal MB, Sermeus W. Systematic review: Effects, design choices, and context of pay-for-performance in health care. BMC Health Serv Res. 2010; 10:247. doi: 10.1186/1472-6963-10-247 PMID: 20731816.
27. Christianson JB, Leatherman S, Sutherland K. Lessons from evaluations of purchaser pay-for-performance programs: a review of the evidence. Med Care Res Rev. 2008; 65:5S-35S. doi: 10.1177/1077558708324236 PMID: 19015377.
28. Ministry of Health and Welfare. The 2012 Statistics of Death. Available: http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f-list-no=312&fod-list-no=2747. Accessed 12 Mar 2016.
29. Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res. 2007; 37 Suppl 2:S101-105. doi: 10. 1111/j.1872-034X.2007.00170.x PMID: 17877468.
30. Kee KM, Lu SN. Hospital-and community-based screenings for hepatocellular carcinoma in Taiwan. Oncology. 2011; 81 Suppl 1:36-40. doi: 10.1159/000333257 PMID: 22212934.
31. National Health Insurance Administration. National Health Insurance Pay-for-perfermance program for chronic hepatitis B and hepatitis C care [in Chinese] Available: http://www.nhi.gov.tw/webdata/webdata.aspx?menu=20&menu-id=712&WD-ID=836&webdata-id=3263. Accessed 12 Mar 2016.
32. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003; 22:61-76. PMID: 12757273.
33. Cheng TM. Taiwan's National Health Insurance system: high value for the dollar. In: Okma KGH and Crivelli L, eds. Six Countries, Six Reform Models - The healthcare reform experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland, and Taiwan: healthcare reforms "under the radar screen". Singapore: World Scientific Publishing Company. 2010: 171-204.
34. National Health Insurance Administration. Introduction of National Health Insurance. Republic of China: Ministry of Health and Welfare, Executive Yuan, 2013.
35. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med. 1998; 17:2265-2281. doi: 10.1002/(SICI)1097-0258(19981015) 17:19<2265::AID-SIM918>3.0.CO;2-B [pii]. PMID: 9802183.
36. Chou YJ, Huang N, Lin IF, Deng CY, Tsai YW, Chen LS, et al. Do physicians and their relatives have a decreased rate of cesarean section? A 4-year population-based study in Taiwan. Birth. 2006; 33:195-202. doi: 10.1111/j.1523-536X.2006.00104.x PMID: 16948719.
37. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70:41-55.
38. Bendavid E, Holmes CB, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA. 2012; 307(19):2060-7. doi: 10.1001/jama.2012.2001 PMID: 22665105.
39. Tan WS, Ding YY, Xia WC, Heng BH. Effects of a population-based diabetes management program in Singapore. Am J Manag Care. 2014; 20(9):e388-98. PMID: 25364875.
40. Kuo RN, Chung KP, Lai MS. Effect of the pay-for-performance program for breast cancer care in Taiwan. Am J Manag Care. 17: e203-11. PMID: 21711072.
41. Lee TT, Cheng SH, Chen CC, Lai MS. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. Am J Manag Care. 2010; 16:65-69. PMID: 20148607.
42. Cheng SH, Lee TT, Chen CC. A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment. Med Care. 2012; 50:109-116. doi: 10.1097/MLR. 0b013e31822d5d36 PMID: 22249920.
43. Tsai WC, Kung PT, Khan M, Campbell C, Yang WT, Lee TF, et al. Effects of pay-for-performance system on tuberculosis default cases control and treatment in Taiwan. J Infect. 2010; 61:235-243. doi: 10. 1016/j.jinf.2010.06.016 PMID: 20624421.
44. Lai CL, Hou YH. The association of clinical guideline adherence and pay-for-performance among patients with diabetes. J Chin Med Assoc. 2013; 76:102-7. doi: 10.1016/j.jcma.2012.06.024 PMID: 23351421.
45. Epstein AM. Will pay for performance improve quality of care? The answer is in the details. N Engl J Med. 2012; 367:1852-1853. doi: 10.1056/NEJMe1212133 PMID: 23134388.
46. Sutton M, Nikolova S, Boaden R, Lester H, McDonald R, Roland M. Reduced mortality with hospital pay for performance in England. N Engl J Med. 2012; 367:1821-1828. doi: 10.1056/NEJMsa1114951 PMID: 23134382.
47. Lee JY, Lee SI, Jo MW. Lessons from healthcare providers' attitudes toward pay-for-performance: what should purchasers consider in designing and implementing a successful program? J Prev Med Public Health. 2012; 45:137-147. doi: 10.3961/jpmph.2012.45.3.137 PMID: 22712040.
48. Park B, Choi KS, Suh M, Shin JY, Jun JK. Factors associated with compliance with recommendations for liver cancer screening in Korea: a nationwide survey in Korea. PLoS one. 2013; 8:e68315. doi: 10. 1371/journal.pone.0068315 PMID: 23840846.
49. Selvapatt N, House H, Brown A. Hepatocellular Carcinoma Surveillance: Are We Utilizing It? Journal of clinical gastroenterology. 2016; 50(1):e8-e12. doi: 10.1097/mcg.0000000000000344 PMID: 26018132.
50. Advanced Epidemiology: Differene-in-Difference Estimation. Available: http://www. advancedepidemiology.org/difference-in-difference-estimation/. Accessed 5 July 2016.